Cardinal reported $47.1 billion in total revenue in its fiscal fourth quarter, up 10.6% from $42.6 billion in the year-earlier quarter. Earnings per share were $0.50, up 25% from $0.40 in the same period last year.

Revenue from Cardinal’s pharmaceuticals-distribution business, its largest unit by sales, rose about 13% in the quarter to $43.3 billion, and segment profit increased 26% to $451 million.

But the company’s medical supplies unit, which sells products such as sterile gloves to hospitals and doctors’ offices, weighed down its overall results. Cardinal’s medical unit sales fell 11% to $3.8 billion, and lost $16 million.

“Medical segment performance was significantly impacted by inflation and supply chain constraints,” said Mr. Kaufmann.

Mr. Kaufmann has worked for more than 30 years at Cardinal in roles including operations, sales and finance. As CEO, Mr. Kaufmann steered the company through a wave of civil litigation related to the company’s distribution of opioid drugs.

In February, Cardinal along with fellow distributors

AmerisourceBergen Corp.

and

McKesson Corp.

agreed to pay a total of $19.5 billion to 46 states over 18 years to resolve lawsuits alleging that the companies flooded areas of the U.S. with opioid pills.

Mr. Hollar has served as Cardinal’s CFO since May 2020, and was previously CFO of

Tenneco Inc.,

a global automotive products and services company.

Write to Joseph Walker at joseph.walker@wsj.com